Impact BioMedical Inc. (NYSE: IBO) Announces 3F™ US Patent Issue
26 September 2024 - 10:30PM
Impact BioMedical Inc. (“IBO”) is pleased to announce that the US
Patent and Trademark Office has issued U.S. Patent No. 11,985,973
entitled “Insect Repelling Composition” developed within IBO’s 3F™
technology platform.
This is in addition to IBO’s prior granted U.S. Patent No.
11,246,310. Both patents include compositions and formulations of
constituents found in plants and fragrances produced by plants,
which, when applied as a natural insect repellent, have the
potential to reduce insect landings and bites experienced in an
outdoor environment. The terms of U.S. Patents 11,985,973 and
11,246,310 will expire in February 2039 and April 2040,
respectively.
This expands Impact BioMedical’s 3F™ patent estate, which
includes insect repellent compositions and anti-microbial
applications in the United States and other countries. It also
further demonstrates IBO’s commitment to discovering, developing,
and patenting unique technologies to meet unmet needs in human
healthcare.
These compositions and/or formulations inhibit the olfactory
receptors either specifically or universally to “blind” the insect
to human presence. Potential applications of the technology include
use as a human insect (e.g., mosquito) repellent and/or as an
addition to detergents, shampoos, or lotions to repel insect
activity.
According to the World Health Organization, vector-borne
diseases account for approximately 17% of all infectious diseases
worldwide. 3F™ insect repellent presents new potential options to
enable outdoor activity free from insect interference with a purely
natural product, unlike currently available alternatives. This
represents significant market potential worldwide (Vector-borne
diseases (who.int))
Upon notification of the patent issue, IBO CEO Frank D. Heuszel
said, “This is another demonstration of success with our business
model delivering new unique proprietary technology with the
potential to address unmet needs in human healthcare. We are now
accelerating discussions with potential partners to move 3F™
rapidly towards the market in the US and other countries
worldwide.”
About Impact BioMedical, Inc.:
Impact BioMedical Inc. discovers, confirms, and patents unique
science and technologies which can be developed into new offerings
in biopharmaceuticals and consumer healthcare and wellness in
collaboration with external partners through research, licensing,
co-development, joint ventures, and other relationships.
Safe Harbor Disclosure:This press release
contains forward-looking statements within the meaning of Section
27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. These statements are subject to risks and
uncertainties that may cause actual results or events to differ
materially from those projected. Readers are cautioned not to place
undue reliance on forward-looking statements, which speak only as
of the date.
Media Contact:Emily MartinEmail:
emartin@impactbiomedinc.com
Investor Relations:info@impactbiomedinc.com
Impact Biomedical (AMEX:IBO)
Historical Stock Chart
From Nov 2024 to Dec 2024
Impact Biomedical (AMEX:IBO)
Historical Stock Chart
From Dec 2023 to Dec 2024